National Institutes Of Health

Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.

Phase 1 study to determine the safety and feasibility of using HERV-E TCR-transduced autologous T Cells in patients with metastatic clear-cell renal-cell carcinoma.

Phase 1 study of adoptive immunotherapy with CD8+ and CD4+ memory T cells transduced to express an HA-1-specific T cell receptor for children and adults with recurrent acute leukemia after allogeneic hematopoietic stem cell transplantation.

Phase 1 dose-escalation clinical trial to determine the phase 2 dose of autologous TIL 1383I TCR gene-modified T cells using a retrovirus for patients with advanced melanoma.

The NIH presented its New Innovator Award to Zachary T. Schug, PhD, assistant professor in the molecular and cellular oncogenesis program at The Wistar Institute in Philadelphia.

The National Institutes of Health have awarded a $2.4 million 4-year grant to Second Sight Medical Products for the development of spatial localization and mapping technology, according to a press release.

The American Association for Cancer Research today released its annual Cancer Progress Report, which reflects how prior investment in the NIH is paying dividends in terms of advances across the spectrum of cancer care.

Historians attribute Philip II of Macedon — father of Alexander the Great — as the source of the motto and political principle known as “divide and conquer.” As a ruling technique, the maxim worked, with Phillip ultimately ruling over most of classical Greece; a success that would be repeated with Julius Caesar and Napoleon Bonaparte in the centuries to follow.

Testing of 14 patients with acute flaccid myelitis, or AFM, showed they had antibodies against enteroviruses, especially EV-D68, in their cerebrospinal fluid at a significantly higher rate than controls, supporting “the plausibility of a link” between enterovirus infection and AFM, researchers reported in mBio.

NCI awarded a 5-year, $11 million grant to NYU Langone Health’s Ronald O. Perelman department of dermatology to develop biomarkers that can predict whether immunotherapy will be effective for specific patients.